Pharmaceuticals News and Research

RSS

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

Endo Pharmaceuticals announced today the commencement of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary. The purpose of the tender offer is to acquire any and all Notes to reduce the consolidated interest expense of Endo.

26 Aug 2009

EPIX Pharmaceuticals' PRX-00023 Therapeutics CNS program in Phase 2B/3 offered for auction sale

Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-00023 Therapeutics Program in Phase 2b/3 will be part of the intellectual property offered for sale at the September 30, 2009 auction.

26 Aug 2009

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6.

26 Aug 2009

Modest decline for hypertension drug industry over the next decade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite generic erosion of many branded agents -- most notably Novartis's Diovan -- the hypertension drug market will experience only modest decline over the next decade.

26 Aug 2009

Recent study shows that eDetailing is a viable means for reaching prescribers

For pharmaceutical sales forces, eDetailing has reemerged as a viable means for reaching prescribers. A recent study by Cutting Edge Information shows that drug companies are implementing eDetailing tools -- and are investing more money than ever in this sales channel.

26 Aug 2009

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

26 Aug 2009

Tikcro Technologies announces financial results for the second-quarter ended June 30, 2009

Tikcro Technologies Ltd. (OTC BB: TIKRF) today reported results for the second quarter and six months ended June 30, 2009.

26 Aug 2009

FDA accepts Labopharm's response for its novel trazodone formulation

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the U.S. Food and Drug Administration (FDA) has accepted Labopharm's response regarding its novel formulation of the antidepressant trazodone as complete and designated it as a Class 2 resubmission. The FDA has assigned Labopharm a new Prescription Drug User Fee Act (PDUFA) action date of February 11, 2010.

26 Aug 2009

Reform efforts focus attention on regional innovations in care delivery

As health reform efforts loom over Congress, news outlets find models of innovation in their own backyards. Geisinger Health System in rural Pennsylvania, a Florida satellite of the Mayo Clinic, Kaiser Permanente Northwest in Oregon and Washington state, and Virginia Commonwealth University Medical Center in Richmond, Va., all get some attention.

26 Aug 2009

Chicago physician segment likely to grow more consolidated in future

HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that while the medical community in Chicago is more consolidated than most large cities, with multiple large physician groups affiliated with health systems, the physician segment is likely to grow even more consolidated in the future.

26 Aug 2009

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Gloucester Pharmaceuticals today announced that it has raised $29 million in a Series D financing. The proceeds will be used to support the ongoing development of romidepsin, a novel histone deacetylase (HDAC) inhibitor for the treatment of T-cell lymphomas and other hematologic malignancies.

26 Aug 2009

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, announced today it has entered into a research collaboration agreement with the PATH Malaria Vaccine Initiative (MVI) to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus (rVSV) vector technology as a preventative malaria vaccine.

26 Aug 2009

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Alvine Pharmaceuticals, Inc. today announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease.

26 Aug 2009

U.S. Patent Office’s patent issuance provides extensive protection to BDSI's drug delivery technology platforms

BioDelivery Sciences International, Inc. today announced the issuance of United States Patent 7,579,019, which will provide additional patent exclusivity for both ONSOLIS and BDSI’s BEMA drug delivery technology platform until at least 2019.

26 Aug 2009

New needle-free injector system for administering human growth hormone launched by Teva

Antares Pharma, Inc. (NYSE Amex: AIS) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) has launched its new Tjet™ needle-free injector system for the administration of human growth hormone (hGH). The Tjet™ device will be available exclusively in combination with the Teva hGH product Tev-Tropin® [somatropin (rDNA) for injection].

26 Aug 2009

ParagonRx's CEO recommends techniques to effectively manage the FDA-mandated REMS program

While many pharmaceutical and biologics companies are getting accustomed to FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) programs for many new and old drugs, most are not adequately preparing for the equally mandatory program evaluations beginning just 1-1/2 years after each REMS is put into effect.

25 Aug 2009

DATATRAK International signs two new studies with a global research-based biopharmaceutical company

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of two new studies with a global research-based biopharmaceutical company.

25 Aug 2009

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has raised an aggregate $5 million of gross proceeds through a private placement of units ("August 2009 Private Placement") and through the exercise of warrants (the "Warrant Exchange") originally issued in connection with its May/June 2008 private placement.

25 Aug 2009

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.

25 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Pharmaceuticals News and Research

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

EPIX Pharmaceuticals' PRX-00023 Therapeutics CNS program in Phase 2B/3 offered for auction sale

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Modest decline for hypertension drug industry over the next decade

Recent study shows that eDetailing is a viable means for reaching prescribers

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Tikcro Technologies announces financial results for the second-quarter ended June 30, 2009

FDA accepts Labopharm's response for its novel trazodone formulation

Reform efforts focus attention on regional innovations in care delivery

Chicago physician segment likely to grow more consolidated in future

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

U.S. Patent Office’s patent issuance provides extensive protection to BDSI's drug delivery technology platforms

New needle-free injector system for administering human growth hormone launched by Teva

ParagonRx's CEO recommends techniques to effectively manage the FDA-mandated REMS program

DATATRAK International signs two new studies with a global research-based biopharmaceutical company

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Event guide: World ADC Asia eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring